# Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

> **NCT00697749** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 230 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HBV-MPL vaccine 208129
- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00697749
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 2000-01
- **Final completion:** 2000-01
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697749, "Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00697749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*